NBRV 外匯新聞

Biopharmaceutical company Nabriva Therapeutics plc (NBRV) announced Monday that it has entered into an exclusive Distribution Agreement with Er-Kim, a leading partner for biotech companies in international markets, for the oral and intravenous formulations of XENLETA (lefamulin).